Related Articles
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib
Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL‑6/STAT3 signaling pathway
Shikonin inhibits proliferation and induces apoptosis in glioma cells via downregulation of CD147
Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells
Shikonin causes apoptosis by disrupting intracellular calcium homeostasis and mitochondrial function in human hepatoma cells